http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The prognostic value of tumor budding in gastric adenocarcinomas: A cross-sectional study
Baydas Tuba,Coban Ganime,Besiroglu Mehmet,Simsek Melih,Shbair Abdallah TM,Topcu Atakan,Yasin Ayse Irem,Seker Mesut,Turk Haci Mehmet 소화기인터벤션의학회 2023 International journal of gastrointestinal interven Vol.12 No.2
Background: Tumor budding is a negative prognostic factor for many solid malignancies. We investigated the relationship between patients’ clinico-pathological characteristics and tumor budding, as well as the effect of budding level on prognosis. Methods: In this retrospective, cross-sectional, and descriptive study at a tertiary university hospital, 104 patients with gastric adenocarcinoma were divided into two groups according to whether they had a high (≥ 10 buds) or low (< 10 buds) level of budding. The patients were retrospectively evaluated.Results: Sixty-two patients had a low level of budding and 42 had a high level of budding. The mean time from the first diagnosis to the last follow-up was significantly longer (P < 0.05) in the low-budding group (27 months) than in the high-budding group (17 months). As the T stage, N stage, grade, and size of the tumor increased, the proportion of patients with high budding was found to be significantly higher (P < 0.05). High tumor budding, an age of 60 or over at diagnosis, a low body mass index, high N stage, presence of lymphovascular invasion, and recurrence were associ-ated with overall survival.Conclusion: Our study supports that budding is a negative prognostic factor in gastric cancer.
Kiziltan, Huriye Senay,Bayir, Ayse Gunes,Tastekin, Didem,Coban, Ganime,Eris, Ali Hikmet,Aydin, Teoman,Mayadagli, Alparslan Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.20
Background: Lung cancer is the most common cancer in males worldwide. The principal mode of treatment in the early stage of non-small cell lung cancer (NSCLC) is surgery. However, five-year survival is only about 15% for all stages. The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status. Materials and Methods: Ten patients diagnosed as inoperable Stage IIIB NSCLC with comorbid disease were assessed retrospectively in Bezmialem Vakif University, Faculty of Medicine, Department of Radiation Oncology, between 2011 to 2013. ECOG performance status was between 3 and 4. Cisplatin was administered at $6mg/m^2$ daily, for 5 days a week concurrently with radiotherapy using 160-200 cGy daily fractions, 54 Gy being the lowest and 63 Gy being the highest dose. Results: Complete response at the primary tumour site was obtained in 20% patients. Grade I esophagitis was seen 70 percent of patients, and the grade II haematological toxicity rate was 20 %. Median survival time was 7 months. Conclusions: Median survival time was reasonable, despite the patients ECOG performance status of 3-4, which is similar to groups even without comorbid disorders in comparison to other published papers in the literature. Acceptable toxicity, high response rates and quality of life of patients are the other favourable features.